Tuberculous hepatitis in renal transplant recipients following alemtuzumab induction therapy

W. Bosch, N. Poowanawittayakom, K. Chaikriangkrai, J. Mendez, W. C. Hellinger, T. A. Gonwa, M. Krishna, S. Pungpapong

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Mycobacterium tuberculosis infection is one of many opportunistic infections in renal transplant recipients, arising either from reactivation of latent infection or de novo infection, occasionally donor derived. M. tuberculosis hepatitis has never been reported in patients who have received alemtuzumab as part of their renal transplant management. We describe 2 patients who underwent deceased-donor renal transplantation following alemtuzumab induction therapy and presented with a febrile syndrome, subsequently diagnosed as tuberculous hepatitis, one with disseminated disease. Both responded well to treatment without significant side effects, resulting in excellent graft function. The importance of chemoprophylaxis should be emphasized to minimize the risk of developing active tuberculosis in patients with latent tuberculosis infection undergoing solid organ transplantation.

Original languageEnglish (US)
Pages (from-to)E33-E39
JournalTransplant Infectious Disease
Issue number1
StatePublished - Feb 2013


  • Alemtuzumab
  • Hepatitis
  • Liver abscess
  • Renal transplantation
  • Tuberculosis

ASJC Scopus subject areas

  • Infectious Diseases
  • Transplantation


Dive into the research topics of 'Tuberculous hepatitis in renal transplant recipients following alemtuzumab induction therapy'. Together they form a unique fingerprint.

Cite this